IN8BIO, Inc.
INAB2.020USD
-0.090-4.27%
Market hours （ET）Quotes delayed by 15 min
5.47MMarket Cap
LossP/E TTM
More Details of IN8BIO, Inc. Company
IN8bio, Inc. is a clinical-stage biopharmaceutical company. The Company is focused on the discovery, development and commercialization of gamma-delta T cell-based immunotherapies for cancer patients. Gamma-delta T cells are a specialized population of T cells that possess properties, including the ability to differentiate between healthy and diseased tissue. The Company's lead program, INB-400, is in a Phase II clinical trial in which autologous, genetically modified gamma-delta T cells are assessed in glioblastoma (GBM). Its additional programs include Phase I trials in solid and hematologic tumors, including INB-200 for GBM and INB-100 for the treatment of patients with hematologic malignancies that are undergoing hematopoietic stem cell transplantation (HSCT). In addition, the Company’s DeltEx platform has yielded a portfolio of preclinical programs, including INB-300 and INB-500, focused on addressing acute myeloid leukemia (AML) and other solid and hematological tumor types.
Company Info
Ticker SymbolINAB
Company nameIN8bio Inc
IPO dateNov 12, 2020
CEOMr. William T. Ho
Number of employees18
Security typeOrdinary Share
Fiscal year-endNov 12
AddressEmpire State Building
CityNEW YORK
Stock exchangeNASDAQ Capital Market Consolidated
CountryUnited States of America
Postal code10118
Phone16466006438
Websitehttps://www.in8bio.com
Ticker SymbolINAB
IPO dateNov 12, 2020
CEOMr. William T. Ho
Company Executives
Name
Name/Position
Position
Shareholding
Change
Mr. Peter C. Brandt
Mr. Peter C. Brandt
Independent Director
Independent Director
26.23K
+26.32%
Dr. Corinne Epperly
Dr. Corinne Epperly
Independent Director
Independent Director
2.73K
--
Ms. Luba Greenwood
Ms. Luba Greenwood
Independent Director
Independent Director
261.00
--
Mr. Alan S. Roemer
Mr. Alan S. Roemer
Independent Chairman of the Board
Independent Chairman of the Board
--
--
Ms. Emily Wang Fairbairn
Ms. Emily Wang Fairbairn
Independent Director
Independent Director
--
--
Dr. Kate Rochlin, Ph.D.
Dr. Kate Rochlin, Ph.D.
Chief Operating Officer
Chief Operating Officer
--
--
Mr. William T. Ho
Mr. William T. Ho
President, Chief Executive Officer, Director
President, Chief Executive Officer, Director
--
--
Mr. Patrick Mccall, CPA
Mr. Patrick Mccall, CPA
Chief Financial Officer
Chief Financial Officer
--
--
Dr. Lawrence S. Lamb, Ph.D.
Dr. Lawrence S. Lamb, Ph.D.
Co-Founder, Executive Vice President, Chief Scientific Officer
Co-Founder, Executive Vice President, Chief Scientific Officer
--
--
Dr. Jeremy R. Graff, Ph.D.
Dr. Jeremy R. Graff, Ph.D.
Independent Director
Independent Director
--
--
Name
Name/Position
Position
Shareholding
Change
Mr. Peter C. Brandt
Mr. Peter C. Brandt
Independent Director
Independent Director
26.23K
+26.32%
Dr. Corinne Epperly
Dr. Corinne Epperly
Independent Director
Independent Director
2.73K
--
Ms. Luba Greenwood
Ms. Luba Greenwood
Independent Director
Independent Director
261.00
--
Mr. Alan S. Roemer
Mr. Alan S. Roemer
Independent Chairman of the Board
Independent Chairman of the Board
--
--
Ms. Emily Wang Fairbairn
Ms. Emily Wang Fairbairn
Independent Director
Independent Director
--
--
Dr. Kate Rochlin, Ph.D.
Dr. Kate Rochlin, Ph.D.
Chief Operating Officer
Chief Operating Officer
--
--
Revenue Breakdown
No Data
No Data
By Business
By Region
No Data
Shareholding Stats
Updated: Wed, Jul 30
Updated: Wed, Jul 30
Shareholders
Shareholder Types
Shareholders
Shareholders
Proportion
Bios Equity Partners, LP.
8.32%
Franklin Advisers, Inc.
5.51%
AIGH Capital Management, LLC.
3.31%
Ho (William Tai Wei)
2.71%
Alyeska Investment Group, L.P.
2.01%
Other
78.13%
Shareholders
Shareholders
Proportion
Bios Equity Partners, LP.
8.32%
Franklin Advisers, Inc.
5.51%
AIGH Capital Management, LLC.
3.31%
Ho (William Tai Wei)
2.71%
Alyeska Investment Group, L.P.
2.01%
Other
78.13%
Shareholder Types
Shareholders
Proportion
Venture Capital
8.39%
Investment Advisor/Hedge Fund
6.56%
Individual Investor
4.30%
Private Equity
3.31%
Investment Advisor
2.56%
Hedge Fund
2.09%
Research Firm
0.02%
Other
72.77%
Institutional Shareholding
Updated: Tue, Jul 1
Updated: Tue, Jul 1
Reporting Period
No. of institutions
Shares Held
Proportion
Change
2025Q2
62
937.80K
27.23%
-132.74K
2025Q1
67
7.37M
36.64%
+2.95M
2024Q4
64
40.67M
56.11%
+11.42M
2024Q3
66
26.31M
53.00%
+3.73M
2024Q2
66
26.43M
54.24%
+1.59M
2024Q1
62
24.15M
55.92%
+314.96K
2023Q4
58
23.08M
53.43%
+4.41M
2023Q3
55
17.49M
62.06%
+5.54M
2023Q2
52
17.21M
67.21%
+7.01M
2023Q1
46
16.24M
65.08%
+6.18M
View more
Shareholder Activity
Name
Shares Held
Proportion
Change
Chg %
Date
Bios Equity Partners, LP.
286.67K
8.32%
--
--
May 02, 2025
Franklin Advisers, Inc.
189.87K
5.51%
--
--
Mar 31, 2025
AIGH Capital Management, LLC.
37.43K
1.09%
-117.33K
-75.81%
Mar 31, 2025
Ho (William Tai Wei)
93.45K
2.71%
--
--
Feb 16, 2025
Alyeska Investment Group, L.P.
69.32K
2.01%
-99.46K
-58.93%
Mar 31, 2025
The Vanguard Group, Inc.
60.10K
1.74%
+12.64K
+26.62%
Mar 31, 2025
Brandt (Peter C)
26.23K
0.76%
+5.46K
+26.32%
Apr 30, 2025
Sigma Planning Corporation
23.36K
0.68%
-11.36K
-32.72%
Mar 31, 2025
Geode Capital Management, L.L.C.
18.95K
0.55%
+1.78K
+10.37%
Mar 31, 2025
Roemer (Alan S.)
13.78K
0.4%
+3.78K
+37.84%
Apr 30, 2025
View more
Related ETFs
Updated: Sat, Aug 2
Updated: Sat, Aug 2
Name
Proportion
iShares Micro-Cap ETF
0%
iShares Micro-Cap ETF
Proportion0%
Dividend
A total of
0.00
USD has been distributed in dividends over the past 5 years.
Date
Dividend
Record Date
Payment Date
Ex-dividend Date
No Data
Stock Split
Date
Type
Ratio
No Data
Date
Type
Ratio
No Data
